Skip to main content

Table 4 Subgroup analysis of safety according to ICI therapy types

From: Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection

 Anti-PD (L)-1 Mono-TherapyAnti-PD (L)-1 plus Chemotherapy
HIV (16)HBV/HCV (30)HIV (5)HBVC/HCV(3)
Any Grade irAEs
N (%)
Grade ≥ 3 irAEs
N (%)
Any
Grade irAEs
N (%)
Grade
≥3
irAEs
N (%)
Any Grade irAEs
N (%)
Grade ≥ 3 irAEs
N (%)
Any Grade irAEs
N (%)
Grade ≥ 3 irAEs
N (%)
Total4 (25)3(19)13(43)a8(27)a1(20)01(33)1(33)
Colitis00220011
Hepatitis21640000
Rash20611000
Hypothyroidism20101000
Pneumonitis22100000
Arthritis00200000
Diabetes Mellitus00110000
Encephalitis00100000
  1. aTwo patients with baseline grade ≥ 2 hepatitis